According to the Pioneer Securities Research Report, BeiGene raised its performance guidelines and accelerated clinical research on the solid tumor pipeline. In the first half of 2026, net profit attributable to shareholders of listed companies was 3.271 billion yuan. The company raised the 2026 annual revenue guide from 436-45.2 billion yuan to 449-46.2 billion yuan; the guidance for the full year 2026 after deducting operating costs and expenses was raised from 4.8-5.5 billion yuan to 65-7.1 billion yuan. Zebutinib has outstanding clinical value and still has great potential for growth. The company plans to submit marketing applications for zebutinib for first-line treatment of MCL adult patients in the US, Europe, China and Japan in the second half of 2026. As the number of patients accumulates, DoT is extended, and new indications expand, it is believed that sales of zebutinib still have great potential to grow. The pipeline of innovative hematologic oncology drugs is complete, and clinical research on the solid tumor pipeline is progressing at an accelerated pace. For lung cancer, the company has initiated the first human trial of BON-110. Maintain an “Overweight” rating.

According to the Pioneer Securities Research Report, BeiGene raised its performance guidelines and accelerated clinical research on the solid tumor pipeline. In the first half of 2026, net profit attributable to shareholders of listed companies was 3.271 billion yuan. The company raised the 2026 annual revenue guide from 436-45.2 billion yuan to 449-46.2 billion yuan; the guidance for the full year 2026 after deducting operating costs and expenses was raised from 4.8-5.5 billion yuan to 65-7.1 billion yuan. Zebutinib has outstanding clinical value and still has great potential for growth. The company plans to submit marketing applications for zebutinib for first-line treatment of MCL adult patients in the US, Europe, China and Japan in the second half of 2026. As the number of patients accumulates, DoT is extended, and new indications expand, it is believed that sales of zebutinib still have great potential to grow. The pipeline of innovative hematologic oncology drugs is complete, and clinical research on the solid tumor pipeline is progressing at an accelerated pace. For lung cancer, the company has initiated the first human trial of BON-110. Maintain an “Overweight” rating.